Subscribe
shutterstock_1139644889_martyn_jandula
Martyn Jandula / Shutterstock.com
30 April 2020Big PharmaSarah Morgan

CJEU hands down SPC guidance in Royalty Pharma

The Court of Justice of the European Union (CJEU) has handed down its  decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates (SPCs).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
SPCs: a deep dive into CJEU case law
23 June 2020   The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Big Pharma
CJEU puts further brakes on SPCs
22 March 2019   The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
SPCs: a deep dive into CJEU case law
23 June 2020   The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Big Pharma
CJEU puts further brakes on SPCs
22 March 2019   The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

More on this story

Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
SPCs: a deep dive into CJEU case law
23 June 2020   The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Big Pharma
CJEU puts further brakes on SPCs
22 March 2019   The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York